All In MedTech

FDA Clearance Tracker · K182057

EasyMax BT Self-Monitoring Blood Glucose System

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: Aug 24, 2018 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Aug 24, 2018

Substantially Equivalent

Time to decision

24 days

Received Jul 31, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Special

Device class

Class II

The decision

FDA number
K182057
Device name
EasyMax BT Self-Monitoring Blood Glucose System
Applicant location
Hsinchu, TW
Received
Jul 31, 2018
Decided
Aug 24, 2018
Decision
Substantially Equivalent
Submission type
Special

Device type

Device class
Class II
Regulation
21 CFR 862.1345

Every decision under product code NBW

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NBW. The earliest in FDA's data is K010403, decided Mar 26, 2001.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Eps Bio Technology Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.